JP4903342B2 - 免疫応答を誘発するための方法および組成物 - Google Patents

免疫応答を誘発するための方法および組成物 Download PDF

Info

Publication number
JP4903342B2
JP4903342B2 JP2001577979A JP2001577979A JP4903342B2 JP 4903342 B2 JP4903342 B2 JP 4903342B2 JP 2001577979 A JP2001577979 A JP 2001577979A JP 2001577979 A JP2001577979 A JP 2001577979A JP 4903342 B2 JP4903342 B2 JP 4903342B2
Authority
JP
Japan
Prior art keywords
chemotaxin
apc
cells
antigen
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001577979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003534250A5 (https=
JP2003534250A (ja
Inventor
トーマス・ジェイ・シャル
デイル・タルボット
Original Assignee
ケモセントリックス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケモセントリックス, インコーポレイテッド filed Critical ケモセントリックス, インコーポレイテッド
Publication of JP2003534250A publication Critical patent/JP2003534250A/ja
Publication of JP2003534250A5 publication Critical patent/JP2003534250A5/ja
Application granted granted Critical
Publication of JP4903342B2 publication Critical patent/JP4903342B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2001577979A 2000-04-21 2001-04-20 免疫応答を誘発するための方法および組成物 Expired - Fee Related JP4903342B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19883900P 2000-04-21 2000-04-21
US60/198,839 2000-04-21
US83481401A 2001-04-12 2001-04-12
US09/834,814 2001-04-12
PCT/US2001/012950 WO2001080882A2 (en) 2000-04-21 2001-04-20 Methods and compositions for eliciting an immune response

Publications (3)

Publication Number Publication Date
JP2003534250A JP2003534250A (ja) 2003-11-18
JP2003534250A5 JP2003534250A5 (https=) 2008-05-29
JP4903342B2 true JP4903342B2 (ja) 2012-03-28

Family

ID=26894197

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001577979A Expired - Fee Related JP4903342B2 (ja) 2000-04-21 2001-04-20 免疫応答を誘発するための方法および組成物

Country Status (9)

Country Link
EP (1) EP1274454B1 (https=)
JP (1) JP4903342B2 (https=)
AT (1) ATE314088T1 (https=)
AU (2) AU2001257148B2 (https=)
CA (1) CA2406853C (https=)
DE (1) DE60116280T2 (https=)
DK (1) DK1274454T3 (https=)
ES (1) ES2256232T3 (https=)
WO (1) WO2001080882A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361329B2 (en) 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
WO2003035106A1 (en) * 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
US8012474B2 (en) 2007-08-02 2011-09-06 Nov Immune S.A. Anti-RANTES antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029728A1 (en) * 1997-12-11 1999-06-17 University Of Maryland Biotechnology Institute Method and composition to enhance the efficacy of a vaccine using chemokines
IL138075A0 (en) * 1998-02-27 2001-10-31 Univ Pennsylvania Vaccines, immunotherapeutics and methods for using the same
DE69929432T2 (de) * 1998-04-22 2006-09-28 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins

Also Published As

Publication number Publication date
EP1274454B1 (en) 2005-12-28
DE60116280T2 (de) 2006-09-21
AU5714801A (en) 2001-11-07
DE60116280D1 (de) 2006-02-02
EP1274454A2 (en) 2003-01-15
DK1274454T3 (da) 2006-05-15
ATE314088T1 (de) 2006-01-15
WO2001080882A3 (en) 2002-04-04
CA2406853C (en) 2012-06-26
AU2001257148B2 (en) 2006-03-30
CA2406853A1 (en) 2001-11-01
ES2256232T3 (es) 2006-07-16
JP2003534250A (ja) 2003-11-18
WO2001080882A2 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
KR101592855B1 (ko) 암 백신 조성물
Boismenu et al. Chemokine expression by intraepithelial γ δ T cells. Implications for the recruitment of inflammatory cells to damaged epithelia
TWI517859B (zh) 癌抗原輔助肽
JP5743315B2 (ja) トランスフェクション方法及びそのための組成物
EP1379552A1 (en) Toll-like receptor 5 ligands and methods of use
US20190352348A1 (en) Peptides and methods for the treatment of diabetes
CN107106655A (zh) 使用白细胞介素‑10治疗疾病和病症的方法
JP4299777B2 (ja) 免疫応答を誘導するための方法および組成物
US20020071825A1 (en) Methods and compositions for inducing an immune response
JP4903342B2 (ja) 免疫応答を誘発するための方法および組成物
US7361329B2 (en) Compositions for inducing an immune response
US20110052622A1 (en) Reishi-mediated enhancement of human tissue progenitor cell adhesion and differentiation
AU2001257148A1 (en) Methods and compositions for eliciting an immune response
Flanagan et al. Chemokines in tumor immunotherapy
WO2003035106A1 (en) Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
WO2002085409A2 (en) Methods and compositions for inducing an immune response to an antigen
KR20090009839A (ko) 면역조절 올리고펩티드
US20050234004A1 (en) Compositions and methods of use of W-peptides
US20060234941A1 (en) Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
EP3447066A1 (en) New ccl2 peptides for use in cancer therapy
US20060008808A1 (en) Compositions and methods for enhancing an immune response
CN112300248A (zh) 一类促进猪机体产生广谱性免疫应答的多肽及其应用
via a CD14-Dependent et al. Treponema pallidum
WO2006105168A2 (en) Enhancing immune responses with bacterial exotoxins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080409

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110208

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110803

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110803

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111213

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120105

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150113

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees